Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices (CDMO) Receives a Buy From Craig-Hallum
Craig-Hallum Sticks to Their Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Decibel Cannabis Company (OtherDBCCF) and Avid Bioservices (CDMO)
Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
Analysts' Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO)
Analysts' Top Healthcare Picks: Trulieve Cannabis (TCNNF), Avid Bioservices (CDMO)
Analysts Are Bullish on Top Healthcare Stocks: Science 37 (SNCE), Avid Bioservices (CDMO)
Craig-Hallum Maintains Buy on Avid Bioservices, Lowers Price Target to $16
Avid Bioservices Analyst Ratings
RBC Cuts Price Target on Avid Bioservices to $7 From $15, Cites Slower Revenue Growth Assumptions Amid 'Challenging' Demand Backdrop; Outperform Kept
Keybanc Maintains Overweight on Avid Bioservices, Lowers Price Target to $14